(RTTNews) – Enliven Therapeutics Inc. (ELVN) introduced up to date, constructive knowledge from the Section 1 medical trial evaluating ELVN-001 in sufferers with continual myeloid leukemia who’ve both failed out there therapies, are illiberal to them, or aren’t candidates for these remedies. ELVN-001 continues to point out medical profit in closely pretreated continual myeloid leukemia sufferers.
In line with the corporate, the up to date knowledge consists of 39 sufferers throughout numerous dose ranges, 18 of whom have been evaluable for molecular response by 24 weeks. In keeping with the 12-week outcomes the Firm introduced in April 2024, a cumulative main molecular response (MMR) fee of 44.4% (8/18) was noticed by 24 weeks in response-evaluable continual myeloid leukemia sufferers. Moreover, ELVN-001 continues to be well-tolerated with no dose reductions and a median therapy length of 20 weeks.
With extra sufferers enrolled and longer comply with up, the corporate mentioned it continues to see anti-chronic myeloid leukemia exercise in a closely pre-treated affected person inhabitants that features sufferers beforehand handled with asciminib. Moreover, ELVN-001’s security profile stays in line with its excessive selectivity, even with longer length and extra sufferers enrolled at greater dose ranges.
The corporate believes the info display the potential medical utility of ELVN-001 for sufferers throughout the total spectrum of the CML therapy paradigm.
For Extra Such Well being Information, go to rttnews.com.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
